Bone Metastasis Market Size, Share, Trends, Research Report- Forecast till 2030
Bone Metastasis Market
The increasing prevalence of breast cancer, growing geriatric
population, rising healthcare expenditures, and increasing R&D expenses by
the key players are estimated to drive the market growth during the forecast
period.
The Bone
Metastasis Market is expected to reach USD 17.34
Billion by 2030 at 9.30% CAGR during the forecast period 2022-2030
Bone
metastasis is a condition that occurs when cancerous cells from a non-bone site
travel, i.e. metastasize, to bones. The spine, particularly the lower spine,
the pelvis, and the thighs, are the most common sites for bone metastases. Bone
metastasis can cause urinary and bowel incontinence, due to it being located
quite close to both the urinary bladder and the rectal column, as well as
hypercalcemia. While all cancers can manifest in this way, breast and prostate
cancers are the likeliest sources of bone metastasis – 65-75% of patients
suffering from breast or prostate cancers experience bone metastasis. The bone
metastasis is not often targeted as a separate physiological condition, with
the treatment of the original cancer remaining the top priority despite the
metastasis. The pain resulting from bone metastases can, however, be combated
with pain medication such as narcotics.
The rising
geriatric population and the increasing prevalence of breast and prostate
cancers is likely to be the major driver for the global bone metastasis market
over the forecast period. The growing cultural awareness about breast and
prostate cancer, thanks to the two being gender-exclusive diseases that can be
marketed as such, is likely to remain a major driver for the global bone
metastasis market, as breast and prostate cancers are among the most researched
types of cancer in the world. The increasing healthcare expenditure, especially
in developing economies, and high amount of efforts in R&D are also likely
to drive the bone metastasis market over the forecast period.
On the other
hand, the high costs of bone metastasis treatments and the lack of advanced
healthcare facilities in emerging regions are likely to restrain the growth of
the bone metastasis market in the coming years. The side effects related to
bone metastasis treatment could also hamper the global bone metastasis market’s
growth over the forecast period.
Major Key Players:
The Bone Metastasis Market
Players are F. Hoffmann-La Roche Ltd (Switzerland)
Bayer AG
(Germany), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG
(Switzerland), Pharmalucence Inc. (England), Koninklijke Philips N.V. (the
Netherlands), GENERAL ELECTRIC (U.S.), Siemens AG (Germany), TOSHIBA
CORPORATION (Japan), and others.
Segment Analysis
The global bone metastasis market is segmented on the
basis of type, diagnosis, treatment, and end-user.
On the basis of type, the market is segmented into
osteolytic bone metastasis, osteoblastic bone metastasis, mixed bone
metastasis, and others. On the basis of diagnosis, the market is categorized
into biopsy, blood test, imaging, and others. The imaging segment is sub-segmented
into X-ray, bone scintigraphy, computerized tomography, magnetic resonance imaging, positron emission tomography, and others. On the basis of
treatment, the market is segmented into medical therapies, surgery, medication,
and others. The medical therapies segment is sub-segmented into chemotherapy, targeted therapy, hormone therapy, ablation therapy, and others.
The surgery segment is sub-segmented into vertebroplasty, kyphoplasty, and
others. The medication segment is sub-segmented into pain medications, bone
building medications, and others. On the basis of end-user, the market is
segmented into hospitals and clinics, diagnostic centers, pharmacies, and
ambulatory surgical centers.
Regional Analysis
The Americas is the leading contributor to the global bone metastasis
market due to the high healthcare expenditure in developed countries such as
Canada and the U.S. and the presence of an advanced healthcare sector that can
handle complications related to cancer with relative ease. In the U.S., more
than 300,000 new cases of invasive and non-invasive breast cancer are expected
to be registered in 2018, while about 1 in 9 men is expected to be diagnosed
with prostate cancer over their lifetime. This is likely to drive the demand
from the bone metastasis market over the forecast period.
Europe is expected to remain the second largest regional segment of the
bone metastasis market due to the consistent technological advancement in the
healthcare sector and the increasing willingness of patients to spend more on
effective cancer treatment.
Asia Pacific is likely to exhibit the highest growth in the global bone
metastasis market over the forecast period due to the growing prevalence of
cancer, whereas the Middle East and Africa market is likely to be dominated by
the Middle East due to the lack of advanced healthcare facilities in most
African countries.
About Market Research
Future
At Market Research Future (MRFR), we enable our
customers to unravel the complexity of various industries through our Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and Market Research &
Consulting Services.
MRFR team have supreme objective to provide the
optimum quality market research and intelligence services to our clients. Our
market research studies by products, services, technologies, applications, end
users, and market players for global, regional, and country level market
segments, enable our clients to see more, know more, and do more, which help to
answer all their most important questions.
In order to stay updated with technology and work
process of the industry, MRFR often plans & conducts meet with the industry
experts and industrial visits for its research analyst members.
Contact us:
Market Research Future
(part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 646 845 9312
Email: sales@marketresearchfuture.com
Comments
Post a Comment